Overview
TH MEDICAL-B (2697)
Guangdong True Health Medical Technology Development Co., Ltd. engages in in the research and development, manufacture and sale of surgical robots and disposabl...
- Open
- 47.800
- High
- 49.360
- Low
- 43.380
- Prev. Close
- 47.000
- Volume
- 825.10K
- Turnover
- 37.87M
- Avg Price
- 45.901
- Bid/Ask Ratio
- 99.56%
- Amplitude
- 12.72%
- 52wk High
- 886.000
- Volume Ratio
- 15.96
- Turnover Ratio
- 2.31%
- 52wk Low
- 41.740
- HK Mkt Cap
- 1.55B
- Market CapHKD
- 1.55B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.03
- EPSDynamic
- -3.90
- EPSStatic
- --
- BVPS
- 17.53
- P/B
- 2.48
- HK Shares
- 35.65M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 35.65M
- Min lot size
- 20
- Currency
- HKD
TH MEDICAL-B Analyst Rating
View moreForecast & Rating
Jul 6, 2026- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
TH Medical-B fell 7.6% to HK$43.42 in a spike-and-fade session: it touched HK$49.00 at 09:50 BJ in the morning, roughly 4.3% above the HK$47.00 prior close, then slid through the afternoon to a HK$43.38 intraday low at 15:57 and settled near the day's bottom on 814,180 shares and HK$37.4mn turnover, a 2.28% turnover rate. The move extends the unwinding of double-digit swings tied to xenotransplant and organ-perfusion headlines, with a weekly recap pointing to fading intraday spikes, while a joint company secretary appointment read as routine governance. Fundamentals show revenue and losses expanding together: Q2 2026 revenue of HK$3.28mn was up more than 33x year on year, yet the net loss widened 12.3% to HK$34.9mn at a -1065% net margin, leaving PE at -14.33 and PB at 2.48. The stock is down 89.1% year to date, 95.1% below its HK$886 52-week high and still under its MA20 of HK$49.77, though it now sits only 4.0% above the HK$41.74 52-week low.
- Nov, 13
TH Medical-B spiked and reversed: it touched HK$61.45 at 09:48 BJ, more than 17% above the prior close of HK$52.40, then slid to close at the session low of HK$47.00, down 10.3% on 10.54% turnover. This extends a pattern already visible this month, with headlines on gene-edited pig liver and organ perfusion work driving a 13.02% single-day jump, but with the perfusion technology still awaiting approval and commercialization doubts building, the stock gave back 20.74% in one session. Q2 revenue of HK$3.275 million, up more than 33-fold year on year, still came with a net loss of HK$34.9 million, EPS of -HK$1.087 and a net margin of -1065%. Year to date the shares are down 88.25%, 94.7% below the 52-week high of HK$886, under the HK$50.72 MA20 and only 12.6% above the 2 November low of HK$41.74, though pipeline progress and the joint company secretary appointment remain items to watch.
- Nov, 12
TH Medical-B (2697.HK) closed up 11.17% at HK$52.25, carving a dip-then-rally profile: the morning session bottomed at HK$45.26 before a one-way afternoon climb to HK$52.50, on 1.88 million shares and HK$92.3 million turnover, a 5.26% turnover rate, supported by renewed attention on Hong Kong small-cap medtech and discussion of its organ perfusion system. Fundamentals remain pre-commercial: Q2 2026 revenue of HK$3.28 million was up roughly 33.6x year on year, yet the net loss widened 12.27% to HK$34.9 million, with PE at -17.25x and PB at 2.98x. The stock has just reclaimed its MA20 of HK$51.44 but sits far below MA60 of HK$275.7, down 86.94% year to date, 94.1% below the 12 August high of HK$886 and only 25.18% above the 2 November low of HK$41.74. Though scepticism over the pace of commercialization has repeatedly hit the shares, including a single-day fall of more than 20%.
- Nov, 6
After a 12% jump the prior session, profit-taking produced a spike-and-fade session, with the shares closing down 5.7% at HK$46.52 after touching HK$50.45 at 09:42 BJ and sliding to HK$46.04 by 11:05 BJ. The organ-perfusion catalyst behind the earlier rebound, preclinical completion of ex-vivo perfusion support using six gene-edited pig livers, has been absorbed, while the passing of a joint company secretary added uncertainty. Fundamentals show revenue off a tiny base with widening losses: Q2 2026 revenue of HK$3.28 million, up more than 33x year on year, yet net loss widened 12.27% to HK$34.9 million, EPS -HK$1.087, with PB 2.65x and a negative PE. Price positioning remains weak: down 88.37% year to date, 94.75% below the 12 August 52-week high of HK$886, and only 11.45% above the 2 November low of HK$41.74. Still, the puncture and ablation robotics pipeline remains one of its few differentiated assets.
- Nov, 5
2697.HK fell 5.1% to HK$49.40 after a 12% rise in the prior session, with the stock opening at HK$51.95, reaching HK$52.45 in the morning session, then sliding to a HK$48.38 afternoon low before closing at HK$49.40. The move extends a volatile rebound from the HK$41.74 52-week low set on 2 November, where organ-perfusion system news had triggered double-digit single-day gains; the shares are still 94.4% below the HK$886 52-week high, down 87.7% year-to-date, and well under the MA20 of HK$74.5 and MA60 of HK$339.1. Q2 2026 revenue was only HK$3.275 million, up 3,355% year-on-year, while net loss reached HK$34.90 million, net margin was -1,065%, EPS was -HK$1.087 and ROE -22.26%, leaving revenue growth and losses moving together. Though the stock remains 18.2% above its November low, price action is still sensitive to news flow.
News
Market Movers · TH Medical falls 6% in Hong Kong trading
Weekly Review · Weekly Recap | TH MEDICAL-B -1.26%, intraday spike gives way
PUBT · Guangdong True Health Names Yip Man Wai Joint Company Secretary
Market Movers · TH Medical surges 12%
PUBT · Guangzhou Industry Investment-Backed Shuimu Medical Opens Device Testing Center in Huangpu
